United States - English - NLM (National Library of Medicine)

viatrexx bio incorporated - bos taurus adrenal gland (unii: m2776swb29) (bos taurus adrenal gland - unii:m2776swb29), sus scrofa adrenal gland (unii: 398iyq16yv) (sus scrofa adrenal gland - unii:398iyq16yv), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), brain-derived neurotrophic factor human (unii: 7171wsg8a2) (brain-derived neurotrophic factor human - unii:7171wsg8a2), prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b), malic acid (unii: 817l1n4ckp) (malic acid - unii:817l1n4ckp), basic fibroblast gro - viatrexx-mesenchyme  a sterile, injectable, biodegradable, clear isotonic liquid that is injected into the various layers of the skin, muscles, ligaments, joints, other body tissues or added to an iv, either as a push or into the bag. this product should not be used in patients with a known hypersensitivity to any ingredient found in the formula, porcine products, isotonic saline or benzyl alcohol, or patients with a history of severe allergies. as with all injections, epinephrine injection (1:1,000) must be immediately available should an acute anaphylactoid reaction occur due to any component of the injection. this product contains 1% benzyl alcohol. benzyl alcohol has been reported to be associated with a fatal "gasping syndrome" in premature infants. due to the benzyl alcohol content, this product should not be given to a pregnant woman. this product should not be used in patients with a known hypersensitivity to any ingredient in this formula, porcine products, isotonic saline or benzyl alcohol, or patie

Israel - English - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa pegol - powder and solvent for solution for injection - turoctocog alfa pegol 1000 iu/vial - treatment and prophylaxis of bleeding in previously treated patients with haemophilia a (congenital factor viii disorder).esperoct® does not contain pharmacologically active quantities of von willebrand factor and is, therefore, unsuitable for the treatment of von willebrand disease.

United States - English - NLM (National Library of Medicine)

sandoz inc. - potassium bicarbonate (unii: hm5z15lebn) (potassium cation - unii:295o53k152) - potassium cation 978 mg - the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene

Singapore - English - HSA (Health Sciences Authority)

il hwa - granules

Singapore - English - HSA (Health Sciences Authority)

il hwa - powder

Singapore - English - HSA (Health Sciences Authority)

il hwa - liquid preparation

Singapore - English - HSA (Health Sciences Authority)

il hwa - liquid preparation

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 5 mg in 1 ml - levofloxacin injection in 5% dextrose is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-suscep

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 5 mg in 1 ml - levofloxacin injection in 5% dextrose is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-suscep

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - mafenide acetate (unii: rq6lp6z0wy) (mafenide - unii:58447s8p4l) - mafenide 85 mg in 1 g - sulfamylon cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns. sulfamylon is contraindicated in patients who are hypersensitive to it. it is not known whether there is cross sensitivity to other sulfonamides.